AidsmapFor people taking tenofovir-based HIV treatment, a urine test could be used at the point of care to indicate adherence and predict viral suppression. Research presented last week at the 30th Conference on Retroviruses and Opportunistic Infections (CROI 2023) in Seattle by Dr Kelly Johnson of University of California San Francisco investigated whether the test is good for TAF (tenofovir alafenamide) as well as TDF (tenofovir disoproxil fumarate). This intervention can provide real-time data on adherence, informing counselling, driving adherence interventions and improving the chances of achieving and maintaining viral suppression.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.